PharmaLogic Launches New Radiopharmaceutical Facility In Los Angeles

PharmaLogic Holdings Corp., a leading contract development and manufacturing organization (CDMO) specializing in radiopharmacy solutions, has proudly unveiled its new radiopharmaceutical production and research facility in Los Angeles, California. This facility, acquired in 2022, has undergone comprehensive renovations and features cutting-edge equipment, reflecting PharmaLogic's commitment to advancing the development of innovative radiopharmaceuticals in the area.

The Los Angeles facility marks a significant enhancement of PharmaLogic's manufacturing and research capabilities. This expansion underscores the company's focus on enhancing patient care through the creation and distribution of novel radiopharmaceuticals designed to address unmet clinical needs. With the newly upgraded production and laboratory spaces, PharmaLogic is poised to increase current production levels while dedicating substantial resources to the research and development of pioneering radiopharmaceuticals.

Steve Chilinski, CEO of PharmaLogic, "We’re thrilled to unveil our new cyclotron facility. Being in Los Angeles enables us to collaborate with leading healthcare providers and researchers promoting the development of novel radiopharmaceuticals and expanding patient access to exciting new radiopharmaceutical diagnostics.”

Scott Holbrook, Chief Strategy Officer and General Manager of PharmaLogic, said in a statement, "Our investment in production and research capabilities is a testament to our commitment to improving patient outcomes through advancements in molecular imaging and theranostics. We aim to empower the medical community with innovative radiopharmaceutical solutions that offer advanced diagnostic capabilities.”